MADRIGAL PHARMACEUTICALS, INC. (MDGL) Net income 2017–2025
MADRIGAL PHARMACEUTICALS, INC. (MDGL) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$288.3MFY2025 · since FY2017: -$31.2M → -$288.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$288.3M | +38.1% |
| FY2024 | -$465.9M | -24.7% |
| FY2023 | -$373.6M | -26.5% |
| FY2022 | -$295.4M | -22.1% |
| FY2021 | -$241.8M | -19.6% |
| FY2020 | -$202.2M | -140.9% |
| FY2019 | -$83.9M | -155.9% |
| FY2018 | -$32.8M | -5.3% |
| FY2017 | -$31.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MDGL financial trends
MDGL RevenueMDGL Net marginMDGL Gross profitMDGL Gross marginMDGL Operating incomeMDGL Operating marginMDGL Operating cash flowMDGL Free cash flowMDGL Capital expendituresMDGL Return on equityMDGL Stock buybacksMDGL Dividends paidMDGL Total assetsMDGL Total liabilitiesMDGL Shareholders’ equityMDGL overview →